Aimed Alliance Submits a Comment to the FDA Regarding the Regulation of Hemp-Derived CBD Products
In response to consumer confusion and certain health and safety risks involving food and supplement…
Browsing: FDA
FDA’s REMS Program Protects Women’s Health
The FDA’s Risk Evaluation and Mitigation Strategies (REMS) program ensures valuable medicines that would not…
Aimed Alliance in Bloomberg: REMS Drug Program Keeps Patients Safe
Aimed Alliance Executive Director, Stacey Worthy, was quoted in a Bloomberg article discussing the U.S.…
Aimed Alliance Addresses Significant Deficiencies in Study Claiming Misuse of Medication Safety Protocols
Aimed Alliance identified significant deficiencies in a new study by Matrix Global Advisors that aimed…
Aimed Alliance To Moderate Panel on Future of Value Based Pricing Initiatives at 2016 FDA/CMS Summit
Aimed Alliance’s Executive Director, Stacey Worthy, will moderate a panel discussion entitled “The Future of…
Aimed Alliance Co-Signs Letter to Senate Judiciary Committee Expressing Concerns that CREATES Act Removes Safety Protections for Patients
Aimed Alliance, one of 16 members of the Patients’ Alliance for Drug Safety Protections (Patients’…
Aimed Alliance’s Op-Ed on REMS Featured in The Hill: “Drug Safety Really Matters”
The Hill has published an op-ed by Aimed Alliance’s Director of Public Policy, Stacey L.…